8-K: Galecto Stockholders Approve Key Governance Proposals at Annual Meeting

Galecto, Inc. announced that all proposals, including director elections, preferred stock conversion, and auditor ratification, were approved by stockholders at its Annual Meeting on June 18, 2025.

Summary

• Galecto, Inc. held its Annual Meeting of stockholders on June 18, 2025.
• Stockholders elected Carl Goldfischer, M.D. and David Shapiro, M.D. as Class II members of the Board of Directors, to serve until the Company's 2028 Annual Meeting of Stockholders. Carl Goldfischer received 219,253 votes for and 23,053 votes withheld, while David Shapiro received 226,360 votes for and 15,946 votes withheld. There were 435,515 broker non-votes for director elections.
• Stockholders approved the issuance of shares of common stock upon conversion of the Series A non-voting convertible preferred stock issued to Bridge Medicines LLC on October 7, 2024, in accordance with Nasdaq Listing Rule 5635(a). This proposal received 226,407 votes for, 15,099 votes against, and 800 votes abstained, with 435,515 broker non-votes.
• Stockholders ratified the selection of EY Godkendt Revisionspartnerselskab as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025. This proposal received 660,974 votes for, 16,319 votes against, and 528 votes abstained, with no broker non-votes.
• The total number of shares of common stock entitled to vote at the Annual Meeting was 1,322,359, and 677,821 shares were present or represented by valid proxy.

Sentiment

Score: 7

Explanation: All proposals presented at the Annual Meeting, including director elections, preferred stock conversion approval, and auditor ratification, were successfully approved by stockholders, indicating strong shareholder alignment with management's recommendations for routine governance matters.

Positives

• All three proposals submitted to stockholders at the Annual Meeting were approved.
• The re-election of Class II directors Carl Goldfischer, M.D. and David Shapiro, M.D. ensures continuity in the Board of Directors.
• Approval of the preferred stock conversion aligns the company with Nasdaq Listing Rule 5635(a) and facilitates the conversion of previously issued preferred stock.
• The ratification of EY Godkendt Revisionspartnerselskab as the independent auditor provides assurance of continued financial oversight for the upcoming fiscal year.

Future Outlook

The elected Class II directors, Carl Goldfischer, M.D. and David Shapiro, M.D., are expected to serve until the Company's 2028 Annual Meeting of Stockholders.

Industry Context

This filing primarily details routine corporate governance matters and shareholder approvals, which are standard procedures for publicly traded companies. It does not provide information to analyze broader industry trends or competitive positioning within the biotechnology or pharmaceutical sector.

Corporate Governance

Related Party Transactions

• Stockholders approved the issuance of common stock upon conversion of Series A non-voting convertible preferred stock issued to Bridge Medicines LLC on October 7, 2024, which was required under Nasdaq Listing Rule 5635(a).

Stakeholder Impact

• Shareholders: Approved all proposals, including the re-election of directors, the preferred stock conversion, and the ratification of the independent auditor, indicating support for the company's governance and financial structure.
• Board of Directors: The re-election of Class II directors ensures continuity and stability in the board's composition.
• Bridge Medicines LLC: The approval of the preferred stock conversion allows for the conversion of their Series A preferred stock into common stock.

Next Steps

• The elected Class II directors, Carl Goldfischer, M.D. and David Shapiro, M.D., will serve until the Company's 2028 Annual Meeting of Stockholders.

Key Dates

Keywords

Galecto Inc., GLTO, Annual Meeting, stockholders, corporate governance, director election, preferred stock conversion, auditor ratification, Nasdaq Listing Rule 5635(a), Bridge Medicines LLC, EY Godkendt Revisionspartnerselskab, SEC filing, 8-K